Genmab A/S (NASDAQ:GMAB) Releases Earnings Results, Beats Estimates By $0.17 EPS

Genmab A/S (NASDAQ:GMAB) released its earnings results on Thursday. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17, Zacks reports. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab raised its 2026 guidance, now expecting revenue of DKK 4.3–4.5 billion and operating profit of DKK 1.1–1.4 billion. Revenue growth at the midpoint is projected at 19%, while operating expenses rise only 2%, highlighting expected operating leverage.
• First-half proprietary-product sales increased 37% to DKK 396 million, led by EPKINLY sales growth of 48% to DKK 312 million. Management cited accelerating U.S. community adoption, broader site activation, and strong uptake of the second-line follicular lymphoma regimen.
• Genmab reported statistically significant, clinically meaningful progression-free-survival results from the phase III EPCORE DLBCL-2 study and received European approval for EPKINLY plus lenalidomide and rituximab in second-line follicular lymphoma.
• Petosemtamab is being expanded into two global phase III colorectal cancer trials—frontline and second-line—in combination with chemotherapy. Management also expects frontline head-and-neck data in the fourth quarter and is positioning the asset as a potential multi-indication growth driver.
• Several major catalysts are expected in the coming quarters, including Rina-S phase II and III ovarian-cancer data and frontline EPKINLY data in the fourth quarter, while petosemtamab’s second- or third-line head-and-neck readout is now expected in the first quarter of 2027. Overall-survival data for the EPKINLY DLBCL study remain immature, and outcomes for these late-stage programs are still subject to clinical and regulatory uncertainty.

Genmab A/S Price Performance

GMAB stock traded up $1.24 during mid-day trading on Friday, hitting $31.07. 2,224,922 shares of the stock were exchanged, compared to its average volume of 1,848,670. The business has a fifty day moving average price of $27.22 and a 200 day moving average price of $27.99. Genmab A/S has a 12 month low of $21.00 and a 12 month high of $35.43. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The stock has a market capitalization of $19.37 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 1.84 and a beta of 0.83.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GMAB. Orbis Allan Gray Ltd increased its position in Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after purchasing an additional 3,340,456 shares during the period. Paradigm Biocapital Advisors LP boosted its stake in shares of Genmab A/S by 84.4% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock valued at $216,827,000 after purchasing an additional 3,222,983 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 5.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock valued at $111,735,000 after buying an additional 188,761 shares during the period. Renaissance Technologies LLC lifted its holdings in Genmab A/S by 23.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock worth $107,580,000 after buying an additional 671,307 shares during the period. Finally, Morgan Stanley lifted its holdings in Genmab A/S by 9.5% in the fourth quarter. Morgan Stanley now owns 1,834,439 shares of the company’s stock worth $56,501,000 after buying an additional 159,865 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and raised their price objective for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Truist Financial started coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings upgraded Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. Finally, HC Wainwright increased their price objective on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.28.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.